BioSpace News Archive

Preclinical data demonstrated statistically significant tumor reduction in SM-88 treated arms versus controls - Builds on confirmed tumor responses achieved in human clinical studies across 15 different cancer types - Multiple monotherapy effects of SM-88 were shown, including increased oxidative stress, disruption of autophagy, and tumor immunomodulation - Preclinical results were demonstrated across multiple tumor types including, pancreatic

Walgreens announced the company is resuming immunization services with additional safety measures in place for pharmacy team members and patients.

Innovatus Capital Partners, LLC (“Innovatus” or the “Firm”), an independent adviser and portfolio management firm with approximately $1.6 billion in assets under management, today announced that it has appointed Geoffrey Duyk, M.D., Ph.D., the founder and Managing Partner of Circularis LP, to its Life Sciences Advisory Board.

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, announced today the formation of a Scientific Advisory Board (SAB) and appointment of five leading oncology experts. The SAB will work closely with Arch Oncology

Heart valve innovator Foldax® , a company reinventing every aspect of the heart valve, from material to design to manufacturing, today announced the closing of a $20 million Series D round of funding. MemorialCare Innovation Fund (MCIF) led the round, with Angel Physicians Fund (APF) and Sayan Bioventures joining as new investors. All existing investors also participated in the round, including BioStar Capital, Kair

The first-ever Canadian study to forecast the growing burden of nonalcoholic fatty liver disease (NAFLD or “fatty liver disease”) and its more severe form, nonalcoholic steatohepatitis (NASH), affirms that the liver conditions are an escalating public health issue, with NASH cases increasing by 35 per cent and deaths expected to double to 49,100 (from 24,400 in 2019) in Canada over the next decade. This press release features

First subjects recently administered immunizations in two studies of 20-valent pneumococcal conjugate vaccine candidate in infants; a pentavalent meningococcal vaccine candidate in adolescents; and a respiratory syncytial virus vaccine candidate in pregnant women

MedTech Innovator , the premier nonprofit accelerator in the medical technology industry, today announced the 50 companies selected to participate in the organization’s flagship four-month Showcase and Accelerator program, featuring the industry’s most transformative device, diagnostic, and digital health technologies from around

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will be held online, June 22-24, 2020. These abstract showcases data from ImmunoID NeXT , the first platform to enable comprehensive analysis of both a

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of single-port robotic surgical technologies, announces that on June 18, 2020, The Nasdaq Stock Market LLC (“Nasdaq”) staff determined that the Company has cured the Market Value of Listed Securities and bid price deficiencies and has regained full compliance with all applicable criteria for c